Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2019

Open Access 01-12-2019 | Metastasis | Research

LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus

Authors: Yingying Jiang, Wei Cao, Kun Wu, Xing Qin, Xiaoning Wang, Yan Li, Binbin Yu, Zhen Zhang, Xu Wang, Ming Yan, Qin Xu, Jianjun Zhang, Wantao Chen

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2019

Login to get access

Abstract

Background

The lncRNA LINC00460 plays crucial roles in several epithelial cancers, although its mechanisms of action differ greatly in different cellular contexts. In this study, we aimed to determine the potential clinical applications of LINC00460 and elucidate the mechanisms by which LINC00460 affects the development and progression of head and neck squamous cell carcinoma (HNSCC).

Methods

The biological functions of LINC00460 were assessed in several epithelial cancer cell lines. The subcellular localization of LINC00460 was evaluated by cell nuclear/cytoplasmic fractionation and fluorescence in situ hybridization. RNA pull-down assays, LS-MS/MS analysis, and RNA and chromatin immunoprecipitation assays were performed to identify the molecular mechanism by which LINC00460 promotes HNSCC progression. The clinical pathological features of LINC00460 and PRDX1 were evaluated in HNSCC tissues and paired adjacent normal tissues.

Results

LINC00460 enhanced HNSCC cell proliferation and metastasis in vitro and in vivo and induced epithelial–mesenchymal transition (EMT). LINC00460 primarily localized within the cytoplasm of HNSCC cells, physically interacted with PRDX1 and facilitated PRDX1 entry into the nucleus. PRDX1 promoted the transcription of LINC00460, forming a positive feedback loop. In addition, PRDX1 also promoted the transcription of EMT-related genes (such as ZEB1, ZEB2 and VIM) through enrichment on gene promoters in the nucleus. LINC00460 effectively induced HNSCC cell EMT in a PRDX1-dependent manner, and PRDX1 mainly mediated the EMT-promoting effect of LINC00460. High levels of LINC00460 and PRDX1 expression were positively associated with lymph metastasis, pathological differentiation and tumor size in HNSCC patients.

Conclusions

LINC00460 promoted EMT in HNSCC cells by facilitating PRDX1 entry into the nucleus. LINC00460 and PRDX1 are promising candidate prognostic predictors and potential targets for cancer therapy for HNSCC.
Appendix
Available only for authorised users
Literature
1.
2.
Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, et al. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest. 2016;126:169–80.PubMedCrossRef
3.
Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11:9–22.PubMedCrossRef
4.
5.
Dhamija S, Diederichs S. From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis. Int J Cancer. 2016;139:269–80.PubMedCrossRef
6.
Dykes IM, Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genomics Proteomics Bioinformatics. 2017;15:177–86.PubMedPubMedCentralCrossRef
7.
Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15:7–21.PubMedCrossRef
8.
Shih JW, Chiang WF, Wu ATH, Wu MH, Wang LY, Yu YL, et al. Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1alpha co-activator driving oral cancer progression. Nat Commun. 2017;8:15874.PubMedPubMedCentralCrossRef
9.
10.
Wang ZY, Hu M, Dai MH, Xiong J, Zhang S, Wu HJ, et al. Upregulation of the long non-coding RNA AFAP1-AS1 affects the proliferation, invasion and survival of tongue squamous cell carcinoma via the Wnt/beta-catenin signaling pathway. Mol Cancer. 2018;17:3.PubMedPubMedCentralCrossRef
11.
Dorji T, Monti V, Fellegara G, Gabba S, Grazioli V, Repetti E, et al. Gain of hTERC: a genetic marker of malignancy in oral potentially malignant lesions. Hum Pathol. 2015;46:1275–81.PubMedCrossRef
12.
Arunkumar G, Murugan AK, Prasanna Srinivasa Rao H, Subbiah S, Rajaraman R, Munirajan AK. Long non-coding RNA CCAT1 is overexpressed in oral squamous cell carcinomas and predicts poor prognosis. Biomed Rep. 2017;6:455–62.PubMedPubMedCentralCrossRef
13.
Cao W, Liu J-n, Liu Z, Wang X, Han Z-G, Ji T, et al. A three-lncRNA signature derived from the Atlas of ncRNA in cancer (TANRIC) database predicts the survival of patients with head and neck squamous cell carcinoma. Oral Oncol. 2017;65:94–101.PubMedCrossRef
14.
Li JR, Sun CH, Li W, Chao RF, Huang CC, Zhou XJ, et al. Cancer RNA-Seq Nexus: a database of phenotype-specific transcriptome profiling in cancer cells. Nucleic Acids Res. 2016;44:D944–51.PubMedCrossRef
15.
Zhang Y, Tao Y, Liao Q. Long noncoding RNA: a crosslink in biological regulatory network. Brief Bioinform. 2018;19:930–45.PubMedCrossRef
16.
Li K, Sun D, Gou Q, Ke X, Gong Y, Zuo Y, et al. Long non-coding RNA linc00460 promotes epithelial-mesenchymal transition and cell migration in lung cancer cells. Cancer Lett. 2018;420:80–90.PubMedCrossRef
17.
Yue QY, Zhang Y. Effects of Linc00460 on cell migration and invasion through regulating epithelial-mesenchymal transition (EMT) in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2018;22:1003–10.PubMed
18.
Ye JJ, Cheng YL, Deng JJ, Tao WP, Wu L. LncRNA LINC00460 promotes tumor growth of human lung adenocarcinoma by targeting miR-302c-5p/FOXA1 axis. Gene. 2018;685:76–84.PubMedCrossRef
19.
Zhao H, Wang Y, Ren X. Nicotine promotes the development of non-small cell lung cancer through activating LINC00460 and PI3K/Akt signaling. Biosci Rep. 2019;39:BSR20182443.PubMedPubMedCentralCrossRef
20.
Liu W, Zhang Y, Chen M, Shi L, Xu L, Zou X. A genome-wide analysis of long noncoding RNA profile identifies differentially expressed lncRNAs associated with esophageal cancer. Cancer Med. 2018;7:4181–9.PubMedPubMedCentralCrossRef
21.
Liang Y, Wu Y, Chen X, Zhang S, Wang K, Guan X, et al. A novel long noncoding RNA linc00460 up-regulated by CBP/P300 promotes carcinogenesis in esophageal squamous cell carcinoma. Biosci Rep. 2017;37:BSR20171019.PubMedPubMedCentralCrossRef
22.
Huang GW, Xue YJ, Wu ZY, Xu XE, Wu JY, Cao HH, et al. A three-lncRNA signature predicts overall survival and disease-free survival in patients with esophageal squamous cell carcinoma. BMC Cancer. 2018;18:147.PubMedPubMedCentralCrossRef
23.
Lian Y, Yan C, Xu H, Yang J, Yu Y, Zhou J, et al. A novel lncRNA, LINC00460, affects cell proliferation and apoptosis by regulating KLF2 and CUL4A expression in colorectal cancer. Mol Ther Nucleic Acids. 2018;12:684–97.PubMedPubMedCentralCrossRef
24.
Wang X, Mo FM, Bo H, Xiao L, Chen GY, Zeng PW, et al. Upregulated expression of long non-coding RNA, LINC00460, suppresses proliferation of colorectal cancer. J Cancer. 2018;9:2834–43.PubMedPubMedCentralCrossRef
25.
Kong YG, Cui M, Chen SM, Xu Y, Xu Y, Tao ZZ. LncRNA-LINC00460 facilitates nasopharyngeal carcinoma tumorigenesis through sponging miR-149-5p to up-regulate IL6. Gene. 2018;639:77–84.PubMedCrossRef
26.
Feng L, Yang B, Tang XD. Long noncoding RNA LINC00460 promotes carcinogenesis via sponging miR-613 in papillary thyroid carcinoma. J Cell Physiol. 2019;234:11431–9.PubMedCrossRef
27.
Liu X, Wen J, Wang H, Wang Y. Long non-coding RNA LINC00460 promotes epithelial ovarian cancer progression by regulating microRNA-338-3p. Biomed Pharmacother. 2018;108:1022–8.PubMedCrossRef
28.
Wang F, Liang S, Liu X, Han L, Wang J, Du Q. LINC00460 modulates KDM2A to promote cell proliferation and migration by targeting miR-342-3p in gastric cancer. Onco Targets Ther. 2018;11:6383–94.PubMedPubMedCentralCrossRef
29.
Zhang S, Xu J, Wang H, Guo H. Downregulation of long noncoding RNA LINC00460 expression suppresses tumor growth in vitro and in vivo in gastric cancer. Cancer Biomark. 2019;24:429–37.PubMedCrossRef
30.
31.
Xing H, Wang S, Li Q, Ma Y, Sun P. Long noncoding RNA LINC00460 targets miR-539/MMP-9 to promote meningioma progression and metastasis. Biomed Pharmacother. 2018;105:677–82.PubMedCrossRef
32.
Wen L, Zhang X, Bian J, Han L, Huang H, He M, et al. The long non-coding RNA LINC00460 predicts the prognosis and promotes the proliferation and migration of cells in bladder urothelial carcinoma. Oncol Lett. 2019;17:3874–80.PubMedPubMedCentral
33.
Xu Z, Wang C, Xiang X, Li J, Huang J. Characterization of mRNA expression and endogenous RNA profiles in bladder cancer based on the cancer genome atlas (TCGA) database. Med Sci Monit. 2019;25:3041–60.PubMedPubMedCentralCrossRef
34.
Zhao G, Fu Y, Su Z, Wu R. How long non-coding RNAs and MicroRNAs mediate the endogenous RNA network of head and neck squamous cell carcinoma: a comprehensive analysis. Cell Physiol Biochem. 2018;50:332–41.PubMedCrossRef
35.
36.
Qin X, Yan M, Wang X, Xu Q, Wang X, Zhu X, et al. Cancer-associated fibroblast-derived IL-6 promotes head and neck cancer progression via the osteopontin-NF-kappa B signaling pathway. Theranostics. 2018;8:921–40.PubMedPubMedCentralCrossRef
37.
Qin X, Guo H, Wang X, Zhu X, Yan M, Wang X, et al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. Genome Biol. 2019;20:12.PubMedPubMedCentralCrossRef
38.
Su X, Wang H, Ge W, Yang M, Hou J, Chen T, et al. An in vivo method to identify microRNA targets not predicted by computation algorithms: p21 targeting by miR-92a in cancer. Cancer Res. 2015;75:2875–85.PubMedCrossRef
39.
Pang B, Wu N, Guan R, Pang L, Li X, Li S, et al. Overexpression of RCC2 enhances cell motility and promotes tumor metastasis in lung adenocarcinoma by inducing epithelial-mesenchymal transition. Clin Cancer Res. 2017;23:5598–610.PubMedCrossRef
40.
Tuvshinjargal N, Lee W, Park B, Han K. PRIdictor: protein-RNA interaction predictor. Biosystems. 2016;139:17–22.PubMedCrossRef
41.
Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29:212–26.PubMedCrossRef
42.
De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.PubMedCrossRef
43.
Wang L, Yang F, Jia LT, Yang AG. Missing links in epithelial-mesenchymal transition: long non-coding RNAs enter the arena. Cell Physiol Biochem. 2017;44:1665–80.PubMedCrossRef
44.
Zhang J, Qin X, Sun Q, Guo H, Wu X, Xie F, et al. Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression. Oncogene. 2015;34:3283–95.PubMedCrossRef
45.
Xu Q, Sun Q, Zhang J, Yu J, Chen W, Zhang Z. Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer. Carcinogenesis. 2013;34:539–49.PubMedCrossRef
46.
Obayashi M, Yoshida M, Tsunematsu T, Ogawa I, Sasahira T, Kuniyasu H, et al. microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer. Oncotarget. 2016;7:8223–39.PubMedPubMedCentralCrossRef
47.
Wang Y, Fu L, Cui M, Wang Y, Xu Y, Li M, et al. Amino acid transporter SLC38A3 promotes metastasis of non-small cell lung cancer cells by activating PDK1. Cancer Lett. 2017;393:8–15.PubMedCrossRef
48.
Reno TA, Tong SW, Wu J, Fidler JM, Nelson R, Kim JY, et al. The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer. BMC Cancer. 2016;16:439.PubMedPubMedCentralCrossRef
49.
50.
Lanson NA Jr, Friedlander PL, Schwarzenberger P, Kolls JK, Wang G. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res. 2003;63:7936–41.PubMed
51.
Paidi SK, Diaz PM, Dadgar S, Jenkins SV, Quick CM, Griffin RJ, et al. Label-free Raman spectroscopy reveals signatures of radiation resistance in the tumor microenvironment. Cancer Res. 2019;79:2054–64.PubMedCrossRefPubMedCentral
52.
Zhang H, Yun S, Batuwangala TD, Steward M, Holmes SD, Pan L, et al. A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. Int J Cancer. 2012;131:956–69.PubMedCrossRef
53.
Laban S, Steinmeister L, Gleissner L, Grob TJ, Grenman R, Petersen C, et al. Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation. Radiother Oncol. 2013;109:286–92.PubMedCrossRef
54.
Rahman MA, Amin AR, Wang D, Koenig L, Nannapaneni S, Chen Z, et al. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clin Cancer Res. 2013;19:3416–28.PubMedPubMedCentralCrossRef
55.
Ding C, Fan X, Wu G. Peroxiredoxin 1 - an antioxidant enzyme in cancer. J Cell Mol Med. 2017;21:193–202.PubMedCrossRef
56.
Baltz AG, Munschauer M, Schwanhausser B, Vasile A, Murakawa Y, Schueler M, et al. The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. Mol Cell. 2012;46:674–90.PubMedCrossRef
57.
Castello A, Fischer B, Eichelbaum K, Horos R, Beckmann BM, Strein C, et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell. 2012;149:1393–406.PubMedCrossRef
58.
Li X, Wang W, Wang J, Malovannaya A, Xi Y, Li W, et al. Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes. Mol Syst Biol. 2015;11:775.PubMedPubMedCentralCrossRef
59.
Khan A, Fornes O, Stigliani A, Gheorghe M, Castro-Mondragon JA, van der Lee R, et al. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res. 2018;46:D260–d6.PubMedCrossRef
60.
Kim JH, Bogner PN, Ramnath N, Park Y, Yu J, Park YM. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res. 2007;13:3875–82.PubMedCrossRef
61.
Yu W, Wu J, Ning ZL, Liu QY, Quan RL. High expression of peroxiredoxin 1 is associated with epithelial-mesenchymal transition marker and poor prognosis in gastric cancer. Med Sci Monit. 2018;24:2259–70.PubMedPubMedCentralCrossRef
62.
Zhang J, Jing X, Niu W, Zhang M, Ge L, Miao C, et al. Peroxiredoxin 1 has an anti-apoptotic role via apoptosis signal-regulating kinase 1 and p38 activation in mouse models with oral precancerous lesions. Oncol Lett. 2016;12:413–20.PubMedPubMedCentralCrossRef
63.
Yanagawa T, Iwasa S, Ishii T, Tabuchi K, Yusa H, Onizawa K, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 2000;156:27–35.PubMedCrossRef
64.
Yanagawa T, Omura K, Harada H, Ishii T, Uwayama J, Nakaso K, et al. Peroxiredoxin I expression in tongue squamous cell carcinomas as involved in tumor recurrence. Int J Oral Maxillofac Surg. 2005;34:915–20.PubMedCrossRef
Metadata
Title
LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus
Authors
Yingying Jiang
Wei Cao
Kun Wu
Xing Qin
Xiaoning Wang
Yan Li
Binbin Yu
Zhen Zhang
Xu Wang
Ming Yan
Qin Xu
Jianjun Zhang
Wantao Chen
Publication date
01-12-2019
Publisher
BioMed Central
Keyword
Metastasis
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2019
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-019-1364-z

Other articles of this Issue 1/2019

Journal of Experimental & Clinical Cancer Research 1/2019 Go to the issue

Research

Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects

Research

SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF

Research

RER1 enhances carcinogenesis and stemness of pancreatic cancer under hypoxic environment

Review

Effects of hyperglycemia on the progression of tumor diseases

Correction

Correction to: Wogonoside inhibits invasion and migration through suppressing TRAF2/4 expression in breast cancer

Research

Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits